Contact Lens Spectrum
Issue link: https://clssupplements.epubxp.com/i/740958
C O N T A C T L E N S S P E C T R U M S P E C I A L E D I T I O N 2 0 1 6 c l s p e c t r u m . c o m 40 4. American Optometric Association. American Eye-Q Survey Re- sults. 2015 (http://www.aoa.org/documents/newsroom/2015_Amer- icanEye-Q_surveyresults.pdf). 5. Efron N, Nichols JJ, Woods CA, Morgan PB. Trends in US contact lens prescribing 2002 to 2014. Optom Vis Sci. 2015;92(7):758-767. 6. Kadence International. Novel Multifocal Quantitative Testing: Eye Care Professional Experience with Presbyopia. July 2012. Data on file. Bausch + Lomb. 7. Diec J, Tilia D, Naduvilath T, Bakaraju RC. Predicting short-term performance of multifocal contact lenses. Eye Contact Lens. E-pub ahead of print: May 26, 2016. 8. Beusterien K, Tsay S, Gholizadeh S, Su Y. Real-world experience with colorectal cancer chemotherapies: patient web forum analysis. Ecancermedicalscience. 2013;7:361. 9. Boeru G, Milanov I, De Robertis F, et al. ExtaviJect(R) 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices (Auckl). 2013;6:175-184. 10. Chaudhuri N, Duck A, Frank R, Holme J, Leonard C. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(1):224-226. 11. Ge JB, Zhang F, Qian JY, Ge L, Liu XB, Zhou J. Six-month clini- cal outcomes of Firebird 2TM sirolimus-eluting stent implantation in real-world patients with coronary artery diseases. Chin Med J (Engl). 2011;124(6):831-835. 12. Han YL, Chen JY, Xu B, et al. Real world clinical perfor- mance of the zotarolimus eluting coronary stent system in Chinese patients: a prospective, multicenter registry study. Chin Med J (Engl). 2011;124(20):3255-3259. 13. Blini M, Rossi GC, Trabucchi G, et al. Ocular hypotensive efficacy and safety of travoprost 0.004% in inadequately controlled primary open-angle glaucoma or ocular hypertension: short-term, multicenter, prospective study. Curr Med Res Opin. 2009;25(1):57-63. 14. Crichton AC, Harasymowycz P, Hutnik CM, et al. Effectiveness of dorzolamide-timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J Ocul Pharmacol Ther. 2010;26(5):503-511. 15. Denis P, Baudouin C, Bron A, et al. First-line latanoprost therapy in ocular hypertension or open-angle glaucoma patients: a 3-month efficacy analysis stratified by initial intraocular pressure. BMC Ophthal- mol. 2010;10:4. 16. Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 2005;21(7):1057-1063. Dr. Rah is senior manager, Medical Affairs, Vision Care at Bausch + Lomb. Dr. Saxon is director, Professional Strategy, Vision Care at Bausch + Lomb. Dr. Reindel is director, Medical Device Clinical Operations and Medical Affairs, Vision Care at Bausch + Lomb. PRESBYOPIA PATIENTS APPRECIATE THE 3-ZONE PROGRESSIVE DESIGN IN A DAILY DISPOSABLE LENS B ausch + Lomb Biotrue Oneday for Presbyopia contact lenses (nesofilcon A) feature the 3-Zone Progressive Design, which is also incorporated in the Bausch + Lomb Ultra for Presbyopia monthly lenses (samfilcon A). Both pro- vide excellent visual performance in a multifocal daily disposable lens. Patients (n=326) who tried Biotrue Oneday for Presbyopia lenses, and who wore the lenses for at least 4 days, participated in a survey designed to examine their level of satisfaction with these lenses. When rating vision: • 91% of respondents agreed that Biotrue Oneday for Presbyopia lenses provide clear vision at near distances (e.g., while reading or using a mobile phone) • 96% of respondents agreed that these lenses provide clear vision at intermediate distances (e.g., while working on a computer or shopping) • 95% of respondents agreed that they provide clear vision at far distances (e.g., while driving or reading a bus number). When rating comfort: • 93% of respondents agreed that Biotrue Oneday for Presbyopia lenses stay comfortable throughout the day • 90% of respondents agreed that these lenses provide comfortable vision throughout the day across all distances • 92% of respondents agreed that these lenses make wearing lenses easier on their eyes. At the end of the trial period, more than 70% of the participants indicated they plan on purchasing Biotrue Oneday for Presbyopia contact lenses. In addition, 95% indicated they would recommend these lenses to friends and family members. Regarding their visit to their eyecare professionals, 99% of respondents agreed with this statement: "I am pleased that my doctor offered me a new product to see if it could help improve my lens wearing/vision correction experience." Bausch + Lomb Ultra, MoistureSeal, 3-Zone Progressive, and Biotrue are registered trademarks of Bausch & Lomb Incorporated or its affiliates. UFP.0269.USA.16